Attention-Deficit/Hyperactivity Disorder Subtypes Defined by Cognition Have a Distinct Neural and Clinical Profile and Differ in Response to Atomoxetine

CONCLUSION: Cognitive performance appears effective for identifying ADHD subtypes that have a distinct neural basis and that may particularly benefit from non-stimulants such as atomoxetine.

via https://pubmed.ncbi.nlm.nih.gov/40681145/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20250730010907&v=2.18.0.post9+e462414